Teva’s patents protecting migraine drug ruled invalid | Lilly’s motion for a new trial denied | ‘The court does not reach this decision nor overturn a jury verdict lightly’ says Judge Alison Burroughs.
An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’.
Long-running legal dispute tackles questions of enablement and ‘undue experimentation’ | Federal Circuit says it is bound by SCOTUS’ findings in Amgen v Sanofi.
Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month.
Court upholds USPTO and the PTAB decisions over blood-oxygen sensor in smartwatches | Ruling finds Masimo patents to be unpatentable and obvious | Only one claim relating to inconsistency to be reversed.
Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.